Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

By sjmartinez • September 19, 2023

VanderWalde A, Bellasea SL, Kendra KL, Khushalani NI, Campbell KM, Scumpia PO, Kuklinski LF, Collichio F, Sosman JA, Ikeguchi A, Victor AI, Truong TG, Chmielowski B, Portnoy DC, Chen Y, Margolin K, Bane C, Dasanu CA, Johnson DB, Eroglu Z, Chandra S, Medina E, Gonzalez CR, Baselga-Carretero I, Vega-Crespo A, Garcilazo IP, Sharon E, Hu-Lieskovan S, Patel SP, Grossmann KF, Moon J, Wu MC, Ribas A. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. Nat Med. 2023 Sep;29(9):2278-2285. doi: 10.1038/s41591-023-02498-y. Epub 2023 Aug 17. PMID: 37592104.

Tags: Dermatology, Hematology/Oncology, Publications

Envudeucitinib, a Potent, Next-Generation, Allosteric Inhibitor of TYK2: A Narrative Review

Armstrong AW, Krueger JG, Strober BE, Stein Gold LF, Desai SR, Muscianisi E, Klyachkin Y, Ucpinar S, Tilley MK, Blauvelt A. Envudeucitinib, a Potent, Next-Generation,[...]

Incubating Artificial Intelligence (AI) Initiatives and Careers in Dermatology

Wongvibulsin S, Primiero CA, Adamson AS, Barata C, Betz-Stablein B, Celebi ME, Dawant B, Guitera P, Kelly KM, Kittler H, Kose K, Landman B, Lehman[...]

Neutrophil Transcriptomic Changes in Severe Sterile Vasoplegic Syndrome Resemble a Distinct Molecular Subtype of Septic Shock

Siletz AE, Kelly-Scumpia KM, Scumpia PO, Street K, Ragkousis V, Shirazi R, Sanaiha Y, Do TH, Shemin R, Kwon M, Crager S, Benharash P, Cryer[...]